General Information of DTP (ID: DTPFTEQ)

DTP Name Organic anion transporting polypeptide 2B1 (SLCO2B1) DTP Info
Gene Name OATP2B1

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
29 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Abiraterone acetate DMANBZI Prostate cancer 2C82.0 Approved [1]
Aliskiren DM1BV7W Hypertension BA00-BA04 Approved [2]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [3]
BOL-303259-X DM2EXC5 Open-angle glaucoma 9C61 Approved [4]
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [5]
Cerivastatin DMXCM7H Hyperlipidaemia 5C80 Approved [6]
Dehydroepiandrosterone sulfate DM4Q80H N. A. N. A. Approved [7]
Digoxin DMQCTIH Arrhythmia BC9Z Approved [8]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [9]
Eltrombopag DMOGFIX Thrombocytopenia 3B64 Approved [10]
Estrone sulfate DMVBIZL Atrophic vaginitis GA30.2 Approved [11]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [12]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [13]
Fluvastatin DM4MDJY Arteriosclerosis BD40 Approved [11]
Glibenclamide DM8JXPZ Diabetic complication 5A2Y Approved [14]
L-Glutamic Acid DM4PUDW Schizophrenia 6A20 Approved [15]
Latanoprost DMI5OXG Ocular hypertension 9C61.01 Approved [4]
lifitegrast DM4WVC5 Dry eye disease 9E1Z Approved [16]
Mesalazine DMOL5IU Diverticulitis Approved [17]
Montelukast DMD157S Allergic asthma CA23.0 Approved [18]
Pemetrexed DMMX2E6 Central nervous system lymphoma 2B33.5 Approved [19]
Pitavastatin DMJH792 Hypercholesterolaemia 5C80.0 Approved [20]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [21]
Pravastatin DM6A0X7 Adult acute monocytic leukemia Approved [22]
Ritonavir DMU764S Human immunodeficiency virus infection 1C62 Approved [23]
Rocuronium DMY9BMK Muscle spasm MB47.3 Approved [8]
Rosuvastatin DMMIQ7G Arteriosclerosis BD40 Approved [24]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [25]
Telmisartan DMS3GX2 Hypertension BA00-BA04 Approved [26]
------------------------------------------------------------------------------------
⏷ Show the Full List of 29 Approved Drug(s)
4 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alilusem DM9R2SD Diuretic vasodilator BA00 Phase 3 [27]
Benzylpenicillin DMS9503 Actinomycosis Phase 3 [9]
Sodium taurocholate DM3GO0J Type-2 diabetes 5A11 Phase 1/2 [22]
Taurocholic Acid DM2LZ8F Type-2 diabetes 5A11 Phase 1/2 [22]
------------------------------------------------------------------------------------
1 Preclinical Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Scutellarin DMJT1E5 N. A. N. A. Preclinical [28]
------------------------------------------------------------------------------------
2 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
bromsulphthalein DM9W2ZV N. A. N. A. Investigative [29]
talinolol DMRTD16 Discovery agent N.A. Investigative [30]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate. 2017 May;77(13):1303-1311.
2 Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. Br J Clin Pharmacol. 2011 May;71(5):718-26.
3 Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos. 2009 May;37(5):1129-37.
4 The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci. 2010 May;51(5):2504-11.
5 Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
6 pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm. 2011 Aug 1;8(4):1303-13.
7 Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS One. 2011;6(5):e20372.
8 Drug Interactions in Infectious Diseases.
9 Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
10 Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent. Drug Metab Dispos. 2011 Jun;39(6):1088-96.
11 Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007 Aug;35(8):1308-14.
12 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
13 The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet Genomics. 2011 Feb;21(2):84-93.
14 Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005 Apr;33(4):518-23.
15 The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.60.1.20)
16 Clinical Pharmacology and Biopharmaceutics review(s)
17 Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos. 2011 Jun;39(6):1097-102.
18 Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans. J Clin Pharmacol. 2013 Nov;53(11):1186-93.
19 Substrate- and pH-specific antifolate transport mediated by organic anion-transporting polypeptide 2B1 (OATP2B1-SLCO2B1). Mol Pharmacol. 2012 Feb;81(2):134-42.
20 Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein/multidrug resistance 1. Drug Metab Pharmacokinet. 2011;26(2):171-9.
21 Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006 Jul;34(7):1229-36.
22 Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45.
23 pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions. J Pharmacol Exp Ther. 2010 Sep 1;334(3):1009-22.
24 Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
25 Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. J Pharm Sci. 2017 Sep;106(9):2688-2694.
26 Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos. 2008 Apr;36(4):796-805.
27 Characterization of the uptake mechanism for a novel loop diuretic, M17055, in Caco-2 cells: involvement of organic anion transporting polypeptide (OATP)-B. Pharm Res. 2007 Jan;24(1):90-8.
28 Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab Dispos. 2012 Oct;40(10):2009-20.
29 Organic anion-transporting polypeptide (OATP) 2B1 contributes to the cellular uptake of theaflavin. Drug Metab Pharmacokinet. 2017 Apr;32(2):145-150.
30 Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J Pharmacol Exp Ther. 2010 Jan;332(1):181-9.